{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:19:25Z","timestamp":1784603965749,"version":"3.55.0"},"reference-count":96,"publisher":"IOS Press","issue":"2","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Brain Plasticity"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Neurological disorders, including neurodegenerative diseases, have a significant negative impact on both patients and society at large. Since the prevalence of most of these disorders increases with age, the consequences for our aging population are only going to grow. It is now acknowledged that neurological disorders are multi-factorial involving disruptions in multiple cellular systems. While each disorder has specific initiating mechanisms and pathologies, certain common pathways appear to be involved in most, if not all, neurological disorders. Thus, it is becoming increasingly important to identify compounds that can modulate the multiple pathways that contribute to disease development or progression. One of these compounds is the flavonol fisetin. Fisetin has now been shown in preclinical models to be effective at preventing the development and\/or progression of multiple neurological disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Huntington\u2019s disease, amyotrophic lateral sclerosis, stroke (both ischemic and hemorrhagic) and traumatic brain injury as well as to reduce age-associated changes in the brain. These beneficial effects stem from its actions on multiple pathways associated with the different neurological disorders. These actions include its well characterized anti-inflammatory and anti-oxidant effects as well as more recently described effects on the regulated cell death oxytosis\/ferroptosis pathway, the gut microbiome and its senolytic activity. Therefore, the growing body of pre-clinical data, along with fisetin\u2019s ability to modulate a large number of pathways associated with brain dysfunction, strongly suggest that it would be worthwhile to pursue its therapeutic effects in humans.<\/jats:p>","DOI":"10.3233\/bpl-200104","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T11:00:33Z","timestamp":1592910033000},"page":"155-166","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":75,"title":["Preventing and Treating Neurological Disorders with the Flavonol Fisetin"],"prefix":"10.3233","volume":"6","author":[{"given":"Pamela","family":"Maher","sequence":"first","affiliation":[{"name":"Salk Institute for Biological Studies"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7437","published-online":{"date-parts":[[2020,12]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.04.005"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2018.03.009"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2018.09.008"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/metabo2020303"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.5661\/bger-28-47"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1368980009992990"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007614613771"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(00)00498-6"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026013394741"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.042"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00214"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2004.02563.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/130.9.2243"},{"key":"e_1_3_2_16_2","unstructured":"HendlerSS. PDR for Nutritional Supplements 2nd edition: Thomson Reuters; 2008."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2741\/s425"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"GoedertMSpillantiniMG. A century of Alzheimer\u2019s disease Science. 2006;314:777\u201381.","DOI":"10.1126\/science.1132814"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70219-2"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-110986"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-7-7"},{"key":"e_1_3_2_23_2","unstructured":"https:\/\/www.alzforum.org\/research-models\/alzheimers-disease."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2006.06.021"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4017"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/917167"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2011.11.015"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2013.10.002"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12185"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glx104"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-016-9795-4"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2004.04.001"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00463-8"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2016-0147"},{"key":"e_1_3_2_35_2","first-page":"S40","article-title":"Parkinson\u2019s disease","volume":"14","author":"Weintraub D","year":"2008","unstructured":"WeintraubDComellaCLHornS. Parkinson\u2019s disease. Am J Manag Care. 2008;14:S40\u2013S69.","journal-title":"Am J Manag Care"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a008888"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-004-0954-y"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009316"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2014.00155"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1039\/C7FO00809K"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","unstructured":"AlikatteKPalleSKumarJRPathakalaN. Fisetin improved rotenone-induced behavioral deficits oxidative changes and mitochondrial dysfunctions in rat model of Parkinson\u2019s disease. J Dietary Suppl. 2020;DOI:10.1080\/19390211.2019.1710646.","DOI":"10.1080\/19390211.2019.1710646"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-006-6242-0"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.3727\/000000007783464687"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20071619"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2008.06310.x"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq460"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.244783"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2018.03.024"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2018.03.008"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.12.1.97"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.534503"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-4949.2012.00972.x"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)29374-0"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.23.5.767"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000015346.00054.8B"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2007.07.061"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2011.189"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1309022"},{"key":"e_1_3_2_59_2","first-page":"1","article-title":"Fisetin prolongs therapy window of brain ischemic stroke using tissue plasminogen activator: A double blind randomized placebo-controlled clinical trial","volume":"25","author":"Wang L","year":"2019","unstructured":"WangLCaoDWuHJiaHYangCZhangL. Fisetin prolongs therapy window of brain ischemic stroke using tissue plasminogen activator: A double blind randomized placebo-controlled clinical trial. Clin ApplThromb Hemost. 2019;25:1\u20138.","journal-title":"Clin ApplThromb Hemost"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2008.07.003"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008924"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1159\/000488117"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2015.10.016"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-0693-8_1"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00071"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2019.11.001"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1177\/0963689717714102"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2018.05.011"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pathmechdis.2.010506.092044"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.205"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607822103"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/361031a0"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2017.12.008"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2017.11.004"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.09.015"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026616666160204121725"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201600025"},{"issue":"75","key":"e_1_3_2_78_2","article-title":"Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy","volume":"194","author":"Kashyap D","year":"2018","unstructured":"KashyapDSharmaASakKTuliHSButtarHSBishayeeA. Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy. Life Sci. 2018;194(75-87).","journal-title":"Life Sci"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2012.4996"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddx040"},{"key":"e_1_3_2_81_2","first-page":"5415","article-title":"Hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function","volume":"38","author":"Fernandez-Fernandez S","year":"2018","unstructured":"Fernandez-FernandezSBobo-JimenezVRequejo-AguilarRSGonzalez-FernandezSReschMCarabias-CarrascoM, et al.Hippocampal neurons require a large pool of glutathione to sustain dendrite integrity and cognitive function. Redox Biol. 2018;38:5415\u201328.","journal-title":"Redox Biol"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123056"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4672"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-19-07455.2001"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2015.158"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.015609"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30356-4"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1223813"},{"key":"e_1_3_2_89_2","first-page":"E4901","article-title":"Plasma metabolomic profiles enhance precision medicine for volunteers of normal health","volume":"2015","author":"Guo L","year":"2015","unstructured":"GuoLMilburnMVRyalsJALonerganSCMitchellMWWulffJE, et al.Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc Natl Acad Sci U S A. 2015;2015:E4901\u2013E10.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"203","key":"e_1_3_2_90_2","article-title":"Fisetin regulates gut microbiota to decrease CCR9+\/CXCR3+\/CD4+ T lymphocytes count and IL-12 secretion to alleviate premature ovarian failure in mice","volume":"12","author":"Lin J","year":"2020","unstructured":"LinJNieXXiongYGongZChenJCehnC, et al.Fisetin regulates gut microbiota to decrease CCR9+\/CXCR3+\/CD4+ T lymphocytes count and IL-12 secretion to alleviate premature ovarian failure in mice. Am J Transl Res. 2020;12(203-247).","journal-title":"Am J Transl Res"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.11.006"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","unstructured":"GerdesEOWZhuYTchkoniaTKirklandJL. Discovery development and future application of senolytics: theories and predictions. FEBS J. 2020. doi:10.1111\/febs.15264.","DOI":"10.1111\/febs.15264"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00016"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12840"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-019-0372-9"},{"key":"e_1_3_2_96_2","doi-asserted-by":"crossref","unstructured":"ZhuYDoornebalEJPirtskhalavaTGiorgadzeNWentworthMFuhrmann-StroissniggH et al. New agents that target senescent cells: the flavone fisetin and the BCL-XL inhibitors A1331852 and A1155463. Aging. 2017;9: 955-63.","DOI":"10.18632\/aging.101202"},{"key":"e_1_3_2_97_2","first-page":"447","article-title":"Challenges of conducting clinical trials of natural products to combat cancer","volume":"14","author":"Paller CJ","year":"2016","unstructured":"PallerCJDenmeadeSRCarducciMA. Challenges of conducting clinical trials of natural products to combat cancer. Clin. Adv. Hematol. Oncol. 2016;14:447\u201355.","journal-title":"Clin. Adv. Hematol. Oncol"}],"container-title":["Brain Plasticity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/BPL-200104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/BPL-200104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/BPL-200104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:35:30Z","timestamp":1777383330000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/BPL-200104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.3233\/BPL-200104"],"URL":"https:\/\/doi.org\/10.3233\/bpl-200104","relation":{},"ISSN":["2213-6304","2213-6312"],"issn-type":[{"value":"2213-6304","type":"print"},{"value":"2213-6312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}